SLC5A2 and hydrops fetalis: The recent adoption of novel drug classes, including sodium-glucose cotransporter 2 inhibitors, alongside sacubitril/valsartan, into first-line guideline-driven medical therapy shows early promise.46 Trials have shown that, in addition to preventing HF hospitalizations in people with CKD,47-49 longer term use of sodium-glucose cotransporter 2 inhibitors has the potential to delay progression of CKD once HF has developed.49 Wider benefits in patients with HFrEF include increased survival, reduced hospitalizations and symptoms, and improved HRQoL.32